Mammary tumourigenesis in a high mammary tumour strain of SHN mice was inhibited significantly by exposure to FIR after 5 months of age, but not by FIR treatment between 1 month and 5 months of age. On the other hand, the formation of preneoplastic nodules was suppressed only by FIR irradiation between 1 month and 5 months of age, indicating that there is a critical period for FIR to inhibit the preneoplastic and neoplastic growth of the mammary glands. The partial inhibition of tumour growth caused by exposure to FIR for both periods was markedly enhanced by the combined administration of bamboo grass leaf extract, an active antitumour agent, in drinking water. The motor activity at 10 months of age was enhanced by FIR irradiation. FIR induced a significant elongation of life span. The findings indicate that an appropriate application of FIR would have beneficial effects at an advanced age.
Introduction

Materials
and Methods
Sample
Sasa Health® (Daiwa Biological Research Institute, Co., Ltd., Kawasaki, Japan), an extract of the leaves of bamboo grass (Sasa senanensis rehder) obtained by alkaline hydrolysis, was used. It was diluted 2.96-fold with tap water (0.088% Fe-chlorophyllin Na). Spontaneous motor activity At 6 and 10 months of age, spontaneous motor activity was measured in experimental groups A and B by Supermex (Muromachi Kikai Co., Ltd., Tokyo, Japan)16), a sensor monitor which was mounted above each cage to detect changes in heat across multiple zones of the cage through an array of Fresnel lenses. The body heat radiated by an animal was detected with paired IR pyroelectric detectors on the sensor head of the monitor. The system could monitor and count all spontaneous movements, both vertical and horizontal, including locomotion, rearing, head-movement, etc. All counts were automatically totaled and recorded at an hourly interval.
Life span
Each mouse was checked for health related conditions everyday and palpated twice a week for mammary tumour. Mice which were moribund or developed mammary tumours were killed under light ether anaesthesia immediately and in a week, respectively.
Survival rate at each month was obtained from the ratio of the number of survivors until that month against the initial number of mice examined.
Growth of normal and preneoplastic mammary glands
After recording the last size of mammary tumours on day 16, mice were killed by decapitation under light ether anaesthesia. The unilateral third thoracic glands were prepared for wholemount evaluation and examined under 10-fold magnification. The degree of normal end-bud formation was rated from 1-7 in increments of 117). The number of preneoplastic mammary hyperplastic alveolar nodules (HAN) was counted and the area of each HAN was measured automatically by the computerized digitizer (Model LA-535: PIAS, Tokyo, Japan).
Weights of carcass and endocrine organs At autopsy, carcass weight deducted mammary tumour weight from whole body weight was recorded.
Anterior pituitary, adrenals and ovaries were removed and weighed.
Statistics
The significance of differences between the control and the experimental groups in mammary tumourigenesis and life span were evaluated by the two-way classification method of analysis of variance18). The difference in the other parameters between the groups was evaluated by Student's t-test. Fig. 1 shows the cumulative incidence of mammary tumours in each group. The control and experimental groups A and B developed the first tumours at 6, 5 and 6 months of age, respectively. In group A relative to the control and group B between 7 and 12 months of age, the mammary tumourigenesis was significantly less severe considering simultaneously the incidence and the onset age of tumours. 
Results
Mammary tumour development
Mammary tumour growth
As shown in Fig. 2 , mammary tumour growth rate on day 16 was lower in both groups A and B than the control; however, the difference was not significant.
The combined treatment with Sasa Health® (groups A + S and B + S) induced a marked suppression of the tumour growth. The difference between group A + S or B + S and the control was significant.
The percentage of mammary tumours with different growth rates on day 16 is illustrated in Fig. 3 . In all experimental groups, especially groups A + S and B + S treated with Sasa Health®, the percentage of tumours with growth rates higher than 200% was less than the control value. Conversely, group A + S or B + S had values higher than the control as well as group A or B in the percentage of tumours with growth rates lower than 100%. 3. Spontaneous motor activity Fig. 4 shows the spontaneous motor activity. At 6 months of age, group A kept on the FIR rack tended to have more activity at total and light phases than group B kept on the normal rack. The differences became more marked at 10 months of age.
Life span
As shown in Fig. 5 , the life span considering the survival rate at each month between 4 and 12 months of age was higher for groups A and B than the control. Furthermore, it was higher for group A than group B between 7 and 12 months of age. Table I shows the growth of normal and preneoplastic mammary gland. The numbers of HAN in groups B and B + S were significantly lower than the control. In other parameters, little difference was observed between the control and either experimental group . 
Growth of normal and preneoplastic mammary glands
Discussion
The present study shows that FIR irradiation between 1 month and 5 months of age apparently suppressed the formation of precancerous HAN; however, it had little effect on mammary tumour development. On the other hand, FIR irradiation after 5 months inhibited mammary tumour development, but little affected HAN formation. While mammary tumour growth was retarded to some extent by both FIR treatments in this study, the inhibition was much more marked when the treatment was given after the appearance of tumour 15); the mean level of tumour-associated EGFR mRNA, which is essential for production of cell surface receptors that bind TGF a and mediate its biological effects, was significantly decreased and anterior pituitary weight and serum leptin level were similarly declined by that treatment. Although most animals in all three groups eventually developed mammary tumours, the life span was elongated in the experimental groups receiving FIR irradiation compared to the control. This would principally be ascribed to the retarded mammary tumour growth in the experimental groups. Furthermore, the longer life span in the experimental mice treated with FIR after 5 months of age would be due to the greater inhibition of mammary tumourigenesis. The stimulated motor activity at an advanced age may contribute to the elongation of life span in FIR irradiated experimental animals. Life span was also elongated in mice continuously exposed to FIR after birth". Finally, the findings in this and previous studies4) suggest that an appropriate application of FIR is beneficial at an advanced age.
